New Drug Formulations of Posaconazole: Brief Clinical Pharmacology Review | CMAC

New Drug Formulations of Posaconazole: Brief Clinical Pharmacology Review

Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(4):249-269

​ Veselov A.V.
azoles antifungals invasive fungal infections posaconazole pharmacokinetics pharmacodynamics
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(4):249-269

Abstract

Posaconazole is a second generation triazole with a broad spectrum of activity, which first appeared on the market in 2005 in the form of a suspension for oral administration. Despite some progress made in the framework of clinical trials, the problems associated with both the features of the pharmacokinetics of an oral suspension, and with the inability to take drug per os in individual patients, led to the obvious limitations of the use of posaconazole in clinical practice. In the period from 2013 to 2014 in Europe and the US new tablet formulation of posaconazole and a solution for intravenous administration have been approved for the use. The emergence of tablets with improved pharmacokinetic parameters, as well as the intravenous form of the drug with the ability to use both in the stepdown approach, and in patients who due to various reasons has no possibility to take posaconazole per os, made a great positive impact on the antifungals selection problem for the treatment and prevention of invasive fungal infections. At the moment, new formulations of posaconazole is not registered in the Russian Federation, however, it seems appropriate to familiarize practitioners with their clinical-pharmacological characteristics

Alexander V. Veselov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Nagappan V., Deresinski S. Posaconazole: a broadspectrum triazole antifungal agent. Clin Infect Dis 2007; 45:1610-7.
  • 2. Sabatelli F., Patel R., Mann P., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009-15.
  • 3. Описание лекарственного препарата НОКСАФИЛ® (NOXAFIL). Доступно по адресу: http://www.vidal.ru/drugs/noxafil__44645.
  • 4. EMEA. Noxafil: Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000610/WC500037784.pdf.
  • 5. Noxafil HIGHLIGHTS OF PRESCRIBING INFORMATION. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf.
  • 6. Gross B., Ihorst G., Jung M., Wasch R., Engelhardt M. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacother 2013; 33:1117-25.
  • 7. Bryant A., Slain D., Cumpston A., Craig M. A post marketing evaluation of posaconazole plasma concentrations in neutropenic patients with hematologic malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 2011; 37:266-9.
  • 8. Li Y., Theuretzbacher U., Clancy C., Nguyen M., Derendorf H. Pharmacokinetic/Pharmacodynamic profile of posaconazole. Clin Pharmacokinet 2010; 49:379-96.
  • 9. Kwon D., Mylonakis E. Posaconazole: a new broadspectrum antifungal agent. Expert Opin Pharmacother 2007; 8:1167-78.
  • 10. Allendoerfer R., Loebenberg D., Rinaldi M., Graybill J. Evaluation of SCH 51048 in an experimental model of pulmonary aspergillosis. Antimicrob Agents Chemother 1995; 39:1345-8.
  • 11. Sugar A., Picard M. Treatment of murine pulmonary blastomycosis with SCH 51048, a broad-spectrum triazole antifungal agent. Antimicrob Agents Chemother 1995; 39:996-7.
  • 12. Karyotakis N., Dignani M., Anaissie E. SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice. Antimicrob Agents Chemother 1995; 39:775-7.
  • 13. Pfaller M., Messer S., Jones R. Activity of new triazole, SCH 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997; 41:233-5.
  • 14. Sugar A., Liu X. In vitro and in vivo activity of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996; 20:1314-6.
  • 15. Galgiani J., Lewis M. In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother 1997; 41:180-3.
  • 16. Graybill J., Bocanegra R., Najvar L., Lobenberg D., Luther M. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 1998; 42:2467-73.
  • 17. Sun Q., Fothergill A., McCarthy D., Rinaldi M., Graybill J. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002; 46:1581-2.
  • 18. Manesh A., John A., Mathew B., et al. Posaconazole: an emerging therapeutic option for invasive rhino-orbitocerebral mucormycosis. Mycoses 2016 Jul 22. doi: 10.1111/myc.12529. [Epub ahead of print].
  • 19. Frampton J., Scott L. Posaconazole: a review of its use in the prophylaxis of invasive fungal infections. Drugs 2008; 68:993-1016.
  • 20. Lass-Florl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs 2011; 71:2405-19.
  • 21. Campoli P., Perlin D., Kristof A., et al. Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis. J Infect Dis 2013; 208:1717-28.
  • 22. Sheppard D., Campoli P., Duarte R. Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story. Haematologica 2014; 99:603-4.
  • 23. Klimko N., Vasilyeva N., Chernenkaya T., et al. Invasive candidiasis in intensive care units: results of prospective multicenter study in Russia. Proceedings of the 25th ECCMID, April 25-28, 2015, Copenhagen, Denmark. Abstr. EV0945.
  • 24. Arendrup M., Jensen R., Meletiadis J., et al. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order. Proceedings of the 55th ICAAC/ICC, September 17-21, 2015, San Diego, USA. Abstr. M-1309.
  • 25. Веселов А.В. Изавуконазол — новый противогрибковый препарат класса триазолов. Проблемы медицинской микологии 2015; 17(4):18-24.
  • 26. Wiederhold N., Fothergill A., McCarthy D., Sanders C., Sutton D. Evaluation of the in vitro potency of itraconazole, voriconazole, and posaconazole and against rare Aspergillus species. Proceedings of the 24th ECCMID, May 10-13, 2014, Barcelona, Spain. Abstr. P-0055.
  • 27. Arendrup M., Cuenca-Estrella M., Lass-Flörl C., et al. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect 2012; 18: E248-50.
  • 28. Arendrup M., Cuenca-Estrella M., Lass-Flörl C., Hope W. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat 2013; 16:81-95.
  • 29. Lipp H. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharma 2010; 70:471-80.
  • 30. Ezzet F., Wexler D., Courtney R., et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44:211-20.
  • 31. Krishna G., Moton A., Ma L., et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53:958-66.
  • 32. Krishna G., Ma L., Vickery D., et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2009; 53:4749-52.
  • 33. Walravens J., Brouwers J., Spriet I., et al. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet 2011; 50:725-34.
  • 34. Krishna G., Ma L., Marinho M., Preston R., O’Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 2012; 67:2725-30.
  • 35. Krishna G., Ma L., Martinho M., et al. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 2012; 56:4196-201.
  • 36. Duarte R., Lopez-Jimenez J., Cornely O., et al. Phase 1b study of new posaconazole tablet for the prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 2014; 58:5758-65.
  • 37. Cornely O., Duarte R., Chandrasaker P., et al. Phase 3 pharmacokinetics and safety study of posaconazole tablet in patients at risk for invasive fungal infection. Proceedings of the 23rd ECCMID, April 27-30, 2013, Berlin, Germany. Abstr. LB2966.
  • 38. Cornely O., Duarte R., Haider S., et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother 2016; 71:718-26.
  • 39. Duarte R., Jimenez J. Phase 1B study of the pharmacokinetics and safety of posaconazole solid oral tablet in patients at risk for invasive fungal infection. Proceedings of the 52nd ICAAC, September 9-12, 2012, San Francisco, USA. Abstr. A-1937.
  • 40. Kraft W., Chang P., van Iersel M., et al. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother 2014; 58:4020-5.
  • 41. Heinz W., Egerer G., Lellek H., Boehme A., Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses 2013; 56:304-10.
  • 42. Miceli M., Perissinotti A., Kauffman C., Couriel D. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses 2015; 58:432-6.
  • 43. Vanstraelen K., Prattes J., Maertens J., et al. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. Eur J Clin Pharmacol 2016; 72:953-63.
  • 44. Pham A., Bubalo J., Lewis J. 2nd, et al. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections. Mycoses 2016 Jan 6. doi: 10.1111/ myc.12452. [Epub ahead of print].
  • 45. Maertens J., Cornely O., Ullmann A., et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother 2014; 58:3610-7.
  • 46. Kersemaekers W., van Iersel T., Nassander U., et al. Pharmacokinetics and safety study of posaconazole IV solution by peripheral administration in healthy subjects. Antimicrob Agents Chemother 2015; 59:1246- 51.
  • 47. Cornely O., Haider S., Grigg A., et al. Phase 3 pharmacokinetics (PK) and safety study of posaconazole (POS) IV in patients (pts) at risk for invasive fungal infection (IFI). Proceedings of the 53rd ICAAC, September 10-13, 2013, Denver, USA. Abstr. A-292.
  • 48. Luke D., Tomaszewski K., Damle B., Schlamm H. Review of basic and clinical pharmacology of sulfobutylether- b -cyclodextrin (SBECD). J Pharm Sci 2010; 99:3291-301.
  • 49. Tang P., Wang L., Ma X., et al. Characterization and in vitro evaluation of the complexes of posaconazole with β- and 2,6-di-O-methyl-β-cyclodextrin. AAPS PharmSciTech 2016 Feb 16. doi: 10.1208/s12249-016- 0497-z. [Epub ahead of print].
  • 50. Nassander U., Kersemaekers W., van Iersel M., et al. Pharmacokinetics and safety study of posaconazole IV solution via peripheral administration in healthy subjects. Proceedings of the 53rd ICAAC, September 10-13, 2013, Denver, USA. Abstr. A-455.
  • 51. Ullmann A., Cornely O., Burchardt A., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50:658-66.
  • 52. Ullmann A., Lipton J., Vesole D., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-47.
  • 53. Ascioglu S., Rex J., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
  • 54. Cornely O., Maertens J., Winston D., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Eng J Med 2007; 356:348-59.
  • 55. Rodriguez G., Kubin C., Chou L., et al. Evaluation of antifungal prophylaxis regimens in acute myeloid leukemia patients receiving induction chemotherapy. Proceedings of the 55th ICAAC/ICC, September 17-21, 2015, San Diego, USA. Abstr. M-1282.
  • 56. Cámara R., Grau S., Jurado M., et al. Cost-effectiveness of tablets of posaconazole compared to oral fluconazole or itraconazole in the prevention of invasive fungal diseases among high-risk neutropenic patients with either acute myelogenous leukaemia or myelodysplastic syndrome in Spain. Proceedings of the 26th ECCMID, April 9-12, 2016, Amsterdam, Netherlands. Abstr. P-1594.
  • 57. Solano С., Slavin M., Marks D., et al. Economic evaluation of voriconazole versus posaconazole as primary prophylaxis for the prevention of invasive fungal infections in patients undergoing allogeneic haematopoietic cell transplant. Proceedings of the 25th ECCMID, April 25-28, 2015, Copenhagen, Denmark. Abstr. O-188.
  • 58. Walsh T., Raad I., Patterson T., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2- 12.
  • 59. Huang X., Wang F., Chen Y., et al. A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy. Future Microbiol 2012; 7:201-9.
  • 60. Kim M., Vikram H., Kusne S., et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 2011; 53:1060-6.
  • 61. Raad I., Hachem R., Herbrecht R., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42:1398-403.
  • 62. Vehreschild J., Birtel A., Vehreschild M., et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013; 39:310-24.
  • 63. Deyo J., Nicolsen N., Lachiewicz A., Kozlowski T. Salvage treatment of mucormycosis post-liver transplant with posaconazole during sirolimus maintenance immunosuppression. J Pharm Pract 2016 Feb 9. doi: 10.1177/0897190016628702. [Epub ahead of print].
  • 64. Jeong W., Haywood P., Shanmuganathan N., et al. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: offtrial experience. J Antimicrob Chemother 2016 Aug 11. doi: 10.1093/jac/dkw322. [Epub ahead of print].
  • 65. Vazquez J. Posaconazole for the management of mucosal candidiasis. Future Microbiol 2007; 2:245-56.
  • 66. Skiest D., Vazquez J., Anstead G., et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44:607-14.
  • 67. Catanzaro A., Cloud G., Stevens D., et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007; 45:562-8.
  • 68. Stevens D., Rendon A., Gaona-Flores V., et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132:952-8.
  • 69. Restrepo A., Tobon A., Clark B., et al. Salvage treatment of histoplasmosis with posaconazole. J Inf 2007; 54:319- 27.
  • 70. Pitisuttithum P., Negroni R., Graybill J., et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745-55.
  • 71. Conant M., Sha B., Proia L. Use of posaconazole delayedrelease tablets for treatment of invasive aspergillosis. Mycoses 2015; 58:313-4.
  • 72. Feldman R., Cockerham L., Buchan B., et al. Treatment of Paecilomyces variotii pneumonia with posaconazole: case report and literature review. Mycoses 2016 Jul 12. doi: 10.1111/myc.12525. [Epub ahead of print].
  • 73. Available from: www.clinicaltrials.gov.
  • 74. Jacinto P., Chandrasekar P. Safety of posaconazole. Expert Opin Drug Saf 2013; 12:265-74.
  • 75. Courtney R., Pai S., Laughlin M., et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47:2788- 95.
  • 76. Moton A., Krishna G., Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharma Ther 2009; 34:301-11.
  • 77. Pettit N., Han Z., delaCruz J., et al. Posaconazole (PCZ) Tablet Formulation Therapeutic Drug Monitoring (TDM) and Toxicity Analysis. Proccedings of the 54th ICAAC, September 5-9, 2014, Washington, DC, USA. Abstr.
  • 78. Bruggemann R., Alffenaar J., Blijlevens N., et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48:1441-58.
  • 79. Krishna G., Sansone-Parsons A., Kantesaria B. Assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin 2007; 23:1415-22.
  • 80. Krishna G., Parsons A., Kantesaria B., Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007; 23:545-52.
  • 81. Wexler D., Courtney R., Richards W., et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21:645-53.
  • 82. Moton A., Ma L., Krishna G., et al. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009; 25:701-7.
  • 83. Robinson C., Chau C., Yerkovich S., et al. Posaconazole in lung transplant recipients: use, tolerability, and efficacy. Transpl Infect Dis 2016; 18:302-8.
  • 84. Greco R., Barbanti M., Lupo Stranghellini M., et al. Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation 2016; 51:1022-4.
  • 85. Krishna G., Ma L., Prasad P., et al. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol 2012; 8:1-10.
  • 86. Available from: http://www.ema.europa.eu/ema/index. jsp?curl=pages/news_and_events/news/2016/06/ news_detail_002557.jsp&mid=WC0b01ac058004d5c1.
  • 87. Shields R., Clancy C., Vadnerkar A., et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother 2011; 55:1308-11.
  • 88. Dolton M., Ray J., Chen S., et al. Multicenter study of posaconazole therapeutic drug monitoring: exposureresponse relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56:5503-10.
  • 89. Wiederhold N., Pennick G., Dorsey S., et al. A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother 2014; 58:424-31.
  • 90. Thompson G. 3rd, Rinaldi M., Pennick G., et al. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother 2009; 53:2223-4.
  • 91. Ashbee H., Barnes R., Johnson E., et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69:1162-76.
  • 92. Martino J., Fisher B., Bosse K., Bagatell R. Suspected posaconazole toxicity in a pediatric oncology patient. Pediatr Blood Cancer 2015; 62:1682.
  • 93. Lerolle N., Porcher R., Touratier S., et al. Breakthrough invasive fungal infections in patients receiving posaconazole primary prophylaxis: a four-year study. Proceedings of the 24th ECCMID, May 10-13, 2014, Barcelona, Spain. Abstr. eP-365.
  • 94. Hoenigl M., Raggam R., Valentin T., et al. Posaconazole plasma concentrations in patients with hematologic malignancies: a cohort study. Proceedings of the 22nd ECCMID, March 31 - April 3, 2012, London, UK. Abstr. P-858.
  • 95. Hoenigl M., Duettmann W., Theiler G., et al. Factors associated with low posaconazole plasma concentrations and impact of structured patient education: a cohort study. Proceedings of the 24th ECCMID, May 10-13, 2014, Barcelona, Spain. Abstr. P-1278.
  • 96. Cattaneo C., Panzali A., Passi A., et al. Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections. Mycoses 2015; 58:362-7.
  • 97. Hoenigl M., Duettmann W., Huber-Krassnitzer B., et al. Correlation of early trough levels (day 4) with steadystate posaconazole plasma concentrations — a cohort study. Proceedings of the 24th ECCMID, May 10-13, 2014, Barcelona, Spain. Abstr. eP-256.
  • 98. Girmenia C., Annino L., Mariotti B., et al. Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration? Med Mycol 2016; 54:445-58.
  • 99. Pappas P., Kauffman C., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62: e1-e50.
  • 100. Ullmann A., Akova M., Herbrecht R., et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012; 18(Suppl 7):53-67.
  • 101. Mousset S., Buchheidt D., Heinz W., et al. Treatment of invasive fungal infections in cancer patients: updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014; 93:13-32.
  • 102. van Burik J., Hare R., Solomon H., et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-5.
  • 103. Doring M., Muller C., Johann P., et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis 2012; 12:263.
  • 104. Doring M., Blume O., Haufe S., et al. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis 2014; 33:629-38.
  • 105. Vanstraelen K., Colita A., Annaert P., et al. Posaconazole dosing strategy in pediatric hematology patients. Proceedings of the 24th ECCMID, May 10-13, 2014, Barcelona, Spain. Abstr. P-1696.
  • 106. Vanstraelen K., Colita A., Bica A., et al. Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area. Pediatr Infect Dis J 2016; 35:183-8.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared